



NC DEPARTMENT OF HEALTH AND HUMAN SERVICES

NC MEDICAID and NC HEALTH CHOICE DIVISION OF HEALTH BENEFITS PREFERRED DRUG LIST REVIEW PANEL MEETING

AGENDA

Thursday, January 12, 2023 9:00 a.m. – 1:00 p.m.
Virtual Online Meeting

- I. Welcome
- II. Introductions / Medicaid Updates
- III. Overview of Panel Activities and Procedures
- IV. Drug Class Reviews, Review of Public Comments and Public Testimony

As a reminder, the PDL Panel meets two times per year (January and July), in addition to reviewing every PDL category at least once per calendar year. Public comments during the 45-day public comment period will still only be allowed for categories the State designates on the publicly posted document. Speakers at the PDL Panel meeting are only allowed for categories listed in the agenda for that meeting. **The categories below contain recommendations that will require a vote by the PDL Panel. Those categories that are highlighted have no State recommendations but are open for discussion:**

ALZHEIMER'S AGENTS

ANALGESICS

1. Opioid Analgesics; Short-Acting Schedule II Opioids
2. NSAIDs

ANTICONVULSANTS

1. Carbamazepine Derivatives
2. Second Generation

ANTI-INFECTIVES - SYSTEMIC

1. Lincosamides and Oxazolidinones
2. Macrolides and Ketolides
3. Nitromidazoles (Gastrointestinal Antibiotics)
4. Tetracycline Derivatives
5. Antifungals
6. Antivirals (Hepatitis B Agents)

7. Antivirals (Herpes Treatments)
8. Antivirals (Influenza)
9. Antibiotics, Inhaled

BEHAVIORAL HEALTH

1. Antidepressants; Other
2. Selective Serotonin Reuptake Inhibitor (SSRI)
3. Antihyperkinesia / ADHD
4. Injectable Antipsychotics; Injectable Long Acting

CARDIOVASCULAR

1. ACE Inhibitor / Diuretic Combinations
2. Angiotensin II Receptor Blockers
3. Angiotensin II Receptor Blocker Combinations
4. Angiotensin II Receptor Blocker Diuretic Combinations
5. Angiotensin II Receptor / Neprilysin Blocker Combinations
6. Anti-Arrhythmics
7. Beta Blockers
8. Beta Blocker Diuretic Combinations
9. Bile Acid Sequestrants
10. Dihydropyridine Calcium Channel Blockers
11. Endothelin Receptor Antagonists
12. Inhaled Prostacyclin Analogs
13. Niacin Derivatives
14. Nitrate Combination
15. Oral Pulmonary Hypertension
16. Antianginal & Anti-Ischemic
17. Sympatholytics And Combinations
18. Cardiovascular, Other

CENTRAL NERVOUS SYSTEM

1. Antimigraine Agents
2. Antimigraine Agents; CGRP Blockers/Modulators; Preventative
3. Antimigraine Agents; CGRP Blockers/Modulators; Acute Treatment
4. Multiple Sclerosis; Injectable
5. Multiple Sclerosis; Oral
6. Sedative Hypnotics
7. Smoking Cessation

ENDOCRINOLOGY

1. Growth Hormone
2. Short Acting Insulin
3. Long Acting Insulin
4. Premixed Rapid Combination Insulin
5. GLP-1 Receptor Agonists and Combinations

6. DPP-IV Inhibitors and Combinations
7. Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor and Combinations

GASTROINTESTINAL

1. Antiemetic-Antivertigo Agents
2. Bile Acid Salts
3. Proton Pump Inhibitors
4. Selective Constipation Agents
5. Ulcerative Colitis; Oral
6. Electrolyte Depleters (Kidney Disease)

GENITOURINARY/RENAL

1. Urinary Antispasmodics

GOUT

HEMATOLOGICS

1. Anticoagulants; Oral
2. Colony Stimulating Factors

OPHTHALMICS

1. Anti-Inflammatory/Immunomodulator
2. Beta Blocker Agents / Combinations
3. Carbonic Anhydrase Inhibitors / Combinations

OTIC

1. Anti-Inflammatory

RESPIRATORY

1. Beta-Adrenergic Handheld, Short Acting
2. Beta-Adrenergic, Nebulizers
3. Inhaled Corticosteroids
4. Inhaled Corticosteroid Combinations
5. Intranasal Rhinitis Agents
6. Low Sedating Antihistamines
7. Low Sedating Antihistamine Combinations

TOPICALS

1. Acne Agents
2. Androgenic Agents
3. NSAIDs
4. Antibiotics; Vaginal
5. Antifungals
6. Immunomodulators; Atopic Dermatitis
7. Imidazoquinolinamines

8. Psoriasis
9. Rosacea Agents
10. Very High Potency Steroids

MISCELLANEOUS

1. Estrogen Agents, Combinations
2. Immunomodulators; Systemic
3. Immunosuppressants
4. Movement Disorders
5. Opioid Antagonists
6. Skeletal Muscle Relaxants

DIABETIC CONTINUOUS GLUCOSE MONITOR SUPPLIES

1. Continuous Glucose Monitor Transmitters / Receivers / Readers
2. Continuous Glucose Monitor Sensors

- V. Closing comments and adjournment